Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

Journal of Cachexia, Sarcopenia and Muscle

Volumn 5, Issue 4, 2014, Pages 307-313

  Fogelman, David R ^a   Holmes, Holly ^a   Mohammed, Khalil ^b   Katz, Matthew H G ^a   Prado, Carla M ^c   Lieffers, Jessica ^d   Garg, Naveen ^a   Varadhachary, Gauri R ^a   Shroff, Rachna ^a   Overman, Michael J ^a   Garrett, Christopher ^a   Wolff, Robert A ^a   Javle, Milind ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Forrest Hills Hospital Forrest   (United States)

^c FLORIDA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Adenocarcinoma; Cachexia; IGF; Insulin Growth Factor; Pancreatic cancer; Sarcopenia

Indexed keywords

DALOTUZUMAB; ERLOTINIB; GEMCITABINE; SOMATOMEDIN C RECEPTOR;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGING SOFTWARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUSCLE MASS; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TREATMENT DURATION;

EID: 84951558339     PISSN: 21905991     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13539-014-0145-y     Document Type: Article

References (15)

1. Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
2. Asano T et al. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 2005;65:9164–8.
3. Maloney EK et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003;63:5073–83.
4. Javle MM, V.G., Shroff RT, Bhosale P, Overman MJ, Weatherly J, Wolff RA, Abbruzzese JL, Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J Clin Oncol, 2010. 28: p. 4039.
5. Hameed M, Harridge SD, Goldspink G. Sarcopenia and hypertrophy: a role for insulin-like growth factor-1 in aged muscle? Exerc Sport Sci Rev. 2002;30:15–9.
6. Musaro A et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195–200.
7. Mourkioti F, Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol. 2005;26:535–42.
8. Adams GR. Role of insulin-like growth factor-I in the regulation of skeletal muscle adaptation to increased loading. Exerc Sport Sci Rev. 1998;26:31–60.
9. Ge X, Zhang Y, Jiang H. Signaling pathways mediating the effects of insulin-like growth factor-I in bovine muscle satellite cells. Mol Cell Endocrinol. 2013;372:23–9.
10. Shen W et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97:2333–8.
11. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 2009;3:269–75.
12. Mitsiopoulos N et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85:115–22.
13. Mourtzakis M et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
14. Frontera WR et al. Strength conditioning in older men: skeletal muscle hypertrophy and improved function. J Appl Physiol. 1988;64:1038–44.
15. Prado CM et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr. 2013;98:1012–9.